drugset / Trial / NCT00437268
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To see how well enzastaurin in combination with irinotecan and cetuximab works versus irinotecan and cetuximab in participants who have progressed within 3 months.
Timeline
- Start
- 2007-03
- Primary completion
- 2009-05
- Completion
- 2009-05
Outcome
Missed primary endpoint
registry analysis (unspecified test); Enzastaurin+Irinotecan+Cetuximab vs Irinotecan+Cetuximab; p = 0.431; Log Rank NCT00437268 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | enzastaurin | Small molecule | 500 mg | Oral |
| Background | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 300 mg/m2 | Intravenous |